Which has better valuation & earnings, RADX or INTS?

Intensity Therapeutics has lower revenue, but higher earnings than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Radiopharm Theranostics $2.35M 21.51 -$24.83M N/A N/A Intensity Therapeutics N/A N/A -$11.61M -$5.71 N/A

Is RADX or INTS more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat Intensity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Radiopharm Theranostics N/A N/A N/A Intensity Therapeutics N/A -136.82% -105.82%

Does the media prefer RADX or INTS?

In the previous week, Intensity Therapeutics had 1 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 2 mentions for Intensity Therapeutics and 1 mentions for Radiopharm Theranostics. Intensity Therapeutics' average media sentiment score of 0.42 beat Radiopharm Theranostics' score of 0.00 indicating that Intensity Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Radiopharm Theranostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Intensity Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, ATHE or INTS?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$7.87M N/A N/A Intensity Therapeutics N/A N/A -$11.61M -$5.71 N/A

Is ATHE or INTS more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Intensity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alterity Therapeutics N/A N/A N/A Intensity Therapeutics N/A -136.82% -105.82%

Does the media favor ATHE or INTS?

In the previous week, Intensity Therapeutics had 1 more articles in the media than Alterity Therapeutics. MarketBeat recorded 2 mentions for Intensity Therapeutics and 1 mentions for Alterity Therapeutics. Intensity Therapeutics' average media sentiment score of 0.42 beat Alterity Therapeutics' score of 0.00 indicating that Intensity Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Intensity Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, INTS or DWTX?

Intensity Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Intensity Therapeutics N/A N/A -$11.61M -$5.71 N/A Dogwood Therapeutics N/A N/A -$34.26M -$10.60 N/A

Is INTS or DWTX more profitable?

Dogwood Therapeutics' return on equity of -108.57% beat Intensity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Intensity Therapeutics N/A -136.82% -105.82% Dogwood Therapeutics N/A -108.57% -30.28%

Does the media refer more to INTS or DWTX?

In the previous week, Intensity Therapeutics had 1 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 2 mentions for Intensity Therapeutics and 1 mentions for Dogwood Therapeutics. Dogwood Therapeutics' average media sentiment score of 0.51 beat Intensity Therapeutics' score of 0.42 indicating that Dogwood Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intensity Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dogwood Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, PDSB or INTS?

PDS Biotechnology is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PDS Biotechnology N/A N/A -$34.50M -$0.67 N/A Intensity Therapeutics N/A N/A -$11.61M -$5.71 N/A

Is PDSB or INTS more profitable?

Intensity Therapeutics' return on equity of -136.82% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets PDS Biotechnology N/A -346.02% -102.36% Intensity Therapeutics N/A -136.82% -105.82%

Does the media prefer CRVO or INTS?

In the previous week, CervoMed had 1 more articles in the media than Intensity Therapeutics. MarketBeat recorded 3 mentions for CervoMed and 2 mentions for Intensity Therapeutics. Intensity Therapeutics' average media sentiment score of 0.42 beat CervoMed's score of 0.00 indicating that Intensity Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CervoMed 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Intensity Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Intensity Therapeutics (INTS) Competitors

$4.70 -0.05 (-1.05%)

Closing price 04:00 PM Eastern

Extended Trading

$4.58 -0.13 (-2.66%)

As of 07:21 PM Eastern

Compare

INTS vs. RADX, ATHE, DWTX, PDSB, and CRVO

Should you buy Intensity Therapeutics stock or one of its competitors? MarketBeat compares Intensity Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Intensity Therapeutics include Radiopharm Theranostics (RADX), Alterity Therapeutics (ATHE), Dogwood Therapeutics (DWTX), PDS Biotechnology (PDSB), and CervoMed (CRVO). These companies are all part of the "med - biomed/gene" industry.

How does Intensity Therapeutics compare to Radiopharm Theranostics?

Radiopharm Theranostics (NASDAQ:RADX) and Intensity Therapeutics (NASDAQ:INTS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

3.7% of Intensity Therapeutics shares are held by institutional investors. 7.6% of Intensity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Intensity Therapeutics had 1 more articles in the media than Radiopharm Theranostics. MarketBeat recorded 2 mentions for Intensity Therapeutics and 1 mentions for Radiopharm Theranostics. Intensity Therapeutics' average media sentiment score of 0.42 beat Radiopharm Theranostics' score of 0.00 indicating that Intensity Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Radiopharm Theranostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Intensity Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Intensity Therapeutics has lower revenue, but higher earnings than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$2.35M	21.51	-$24.83M	N/A	N/A
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A

Radiopharm Theranostics currently has a consensus target price of $11.00, suggesting a potential upside of 157.01%. Intensity Therapeutics has a consensus target price of $37.50, suggesting a potential upside of 697.87%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intensity Therapeutics is more favorable than Radiopharm Theranostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Radiopharm Theranostics' return on equity of 0.00% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Intensity Therapeutics	N/A	-136.82%	-105.82%

Radiopharm Theranostics has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Intensity Therapeutics has a beta of 2.78, indicating that its share price is 178% more volatile than the broader market.

Summary

Intensity Therapeutics beats Radiopharm Theranostics on 9 of the 12 factors compared between the two stocks.

How does Intensity Therapeutics compare to Alterity Therapeutics?

Alterity Therapeutics (NASDAQ:ATHE) and Intensity Therapeutics (NASDAQ:INTS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Alterity Therapeutics has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market. Comparatively, Intensity Therapeutics has a beta of 2.78, indicating that its share price is 178% more volatile than the broader market.

2.1% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 3.7% of Intensity Therapeutics shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by company insiders. Comparatively, 7.6% of Intensity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A

In the previous week, Intensity Therapeutics had 1 more articles in the media than Alterity Therapeutics. MarketBeat recorded 2 mentions for Intensity Therapeutics and 1 mentions for Alterity Therapeutics. Intensity Therapeutics' average media sentiment score of 0.42 beat Alterity Therapeutics' score of 0.00 indicating that Intensity Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Intensity Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alterity Therapeutics presently has a consensus price target of $13.00, suggesting a potential upside of 174.26%. Intensity Therapeutics has a consensus price target of $37.50, suggesting a potential upside of 697.87%. Given Intensity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Intensity Therapeutics is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Alterity Therapeutics' return on equity of 0.00% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Intensity Therapeutics	N/A	-136.82%	-105.82%

Summary

Intensity Therapeutics beats Alterity Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Intensity Therapeutics compare to Dogwood Therapeutics?

Intensity Therapeutics (NASDAQ:INTS) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

Intensity Therapeutics currently has a consensus price target of $37.50, suggesting a potential upside of 697.87%. Dogwood Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 769.57%. Given Dogwood Therapeutics' higher probable upside, analysts clearly believe Dogwood Therapeutics is more favorable than Intensity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Intensity Therapeutics had 1 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 2 mentions for Intensity Therapeutics and 1 mentions for Dogwood Therapeutics. Dogwood Therapeutics' average media sentiment score of 0.51 beat Intensity Therapeutics' score of 0.42 indicating that Dogwood Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intensity Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dogwood Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dogwood Therapeutics' return on equity of -108.57% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-136.82%	-105.82%
Dogwood Therapeutics	N/A	-108.57%	-30.28%

3.7% of Intensity Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are owned by institutional investors. 7.6% of Intensity Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Intensity Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

Intensity Therapeutics has a beta of 2.78, meaning that its stock price is 178% more volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market.

Summary

Intensity Therapeutics beats Dogwood Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Intensity Therapeutics compare to PDS Biotechnology?

PDS Biotechnology (NASDAQ:PDSB) and Intensity Therapeutics (NASDAQ:INTS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

PDS Biotechnology has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market. Comparatively, Intensity Therapeutics has a beta of 2.78, meaning that its stock price is 178% more volatile than the broader market.

PDS Biotechnology is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A

In the previous week, Intensity Therapeutics had 2 more articles in the media than PDS Biotechnology. MarketBeat recorded 2 mentions for Intensity Therapeutics and 0 mentions for PDS Biotechnology. Intensity Therapeutics' average media sentiment score of 0.42 beat PDS Biotechnology's score of 0.00 indicating that Intensity Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PDS Biotechnology	Neutral
Intensity Therapeutics	Neutral

PDS Biotechnology currently has a consensus target price of $9.00, suggesting a potential upside of 1,154.71%. Intensity Therapeutics has a consensus target price of $37.50, suggesting a potential upside of 697.87%. Given PDS Biotechnology's higher possible upside, research analysts plainly believe PDS Biotechnology is more favorable than Intensity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Intensity Therapeutics' return on equity of -136.82% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-346.02%	-102.36%
Intensity Therapeutics	N/A	-136.82%	-105.82%

26.8% of PDS Biotechnology shares are held by institutional investors. Comparatively, 3.7% of Intensity Therapeutics shares are held by institutional investors. 8.4% of PDS Biotechnology shares are held by company insiders. Comparatively, 7.6% of Intensity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Intensity Therapeutics beats PDS Biotechnology on 8 of the 13 factors compared between the two stocks.

How does Intensity Therapeutics compare to CervoMed?

CervoMed (NASDAQ:CRVO) and Intensity Therapeutics (NASDAQ:INTS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Intensity Therapeutics has lower revenue, but higher earnings than CervoMed. CervoMed is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	$4.01M	9.41	-$26.97M	-$3.28	N/A
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A

25.2% of CervoMed shares are held by institutional investors. Comparatively, 3.7% of Intensity Therapeutics shares are held by institutional investors. 35.8% of CervoMed shares are held by insiders. Comparatively, 7.6% of Intensity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

CervoMed presently has a consensus price target of $22.60, indicating a potential upside of 710.04%. Intensity Therapeutics has a consensus price target of $37.50, indicating a potential upside of 697.87%. Given CervoMed's higher probable upside, analysts clearly believe CervoMed is more favorable than Intensity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

CervoMed has a beta of -0.68, meaning that its stock price is 168% less volatile than the broader market. Comparatively, Intensity Therapeutics has a beta of 2.78, meaning that its stock price is 178% more volatile than the broader market.

In the previous week, CervoMed had 1 more articles in the media than Intensity Therapeutics. MarketBeat recorded 3 mentions for CervoMed and 2 mentions for Intensity Therapeutics. Intensity Therapeutics' average media sentiment score of 0.42 beat CervoMed's score of 0.00 indicating that Intensity Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CervoMed	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Intensity Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Intensity Therapeutics has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. CervoMed's return on equity of -136.08% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-136.08%	-112.62%
Intensity Therapeutics	N/A	-136.82%	-105.82%

Summary

CervoMed and Intensity Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Intensity Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INTS vs. The Competition

Export

Metric	Intensity Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.84M	$3.69B	$6.90B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.36%
P/E Ratio	-0.82	10.89	22.26	21.51
Price / Sales	N/A	300.39	517.96	91.07
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	0.95	7.92	10.66	6.14
Net Income	-$11.61M	$23.81M	$3.60B	$331.74M
7 Day Performance	-4.47%	-1.27%	-1.51%	-1.72%
1 Month Performance	19.90%	2.56%	1.11%	-1.44%
1 Year Performance	-41.80%	42.49%	23.77%	16.97%

Intensity Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INTS Intensity Therapeutics	2.6731 of 5 stars	$4.70 -1.1%	$37.50 +697.9%	-41.2%	$12.84M	N/A	N/A	2,021
RADX Radiopharm Theranostics	2.5765 of 5 stars	$4.29 +1.1%	$11.00 +156.7%	+0.0%	$50.09M	$2.35M	N/A	N/A
ATHE Alterity Therapeutics	2.914 of 5 stars	$5.58 +1.6%	$13.00 +133.0%	-0.4%	$48.68M	N/A	N/A	10	Analyst Forecast
DWTX Dogwood Therapeutics	2.3874 of 5 stars	$1.41 -2.1%	$12.00 +751.1%	-71.4%	$48.43M	N/A	N/A	5	News Coverage
PDSB PDS Biotechnology	2.4393 of 5 stars	$0.82 -1.2%	$9.00 +991.0%	-36.1%	$46.61M	N/A	N/A	20	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INTS) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intensity Therapeutics (INTS) Competitors

INTS vs. RADX, ATHE, DWTX, PDSB, and CRVO

How does Intensity Therapeutics compare to Radiopharm Theranostics?

Summary

How does Intensity Therapeutics compare to Alterity Therapeutics?

Summary

How does Intensity Therapeutics compare to Dogwood Therapeutics?

Summary

How does Intensity Therapeutics compare to PDS Biotechnology?

Summary

How does Intensity Therapeutics compare to CervoMed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INTS vs. The Competition

Intensity Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Intensity Therapeutics (INTS) Competitors

INTS vs. RADX, ATHE, DWTX, PDSB, and CRVO

How does Intensity Therapeutics compare to Radiopharm Theranostics?

Do institutionals and insiders hold more shares of RADX or INTS?

Does the media prefer RADX or INTS?

Which has better valuation & earnings, RADX or INTS?

Do analysts prefer RADX or INTS?

Is RADX or INTS more profitable?

Which has more risk and volatility, RADX or INTS?

Summary

How does Intensity Therapeutics compare to Alterity Therapeutics?

Which has more volatility and risk, ATHE or INTS?

Do institutionals & insiders hold more shares of ATHE or INTS?

Which has preferable earnings and valuation, ATHE or INTS?

Does the media favor ATHE or INTS?

Do analysts prefer ATHE or INTS?

Is ATHE or INTS more profitable?

Summary

How does Intensity Therapeutics compare to Dogwood Therapeutics?

Do analysts recommend INTS or DWTX?

Does the media refer more to INTS or DWTX?

Is INTS or DWTX more profitable?

Do insiders and institutionals hold more shares of INTS or DWTX?

Which has higher earnings and valuation, INTS or DWTX?

Which has more risk & volatility, INTS or DWTX?

Summary

How does Intensity Therapeutics compare to PDS Biotechnology?

Which has more volatility and risk, PDSB or INTS?

Which has stronger earnings and valuation, PDSB or INTS?

Does the media prefer PDSB or INTS?

Do analysts rate PDSB or INTS?

Is PDSB or INTS more profitable?

Do institutionals & insiders believe in PDSB or INTS?

Summary

How does Intensity Therapeutics compare to CervoMed?

Which has better valuation and earnings, CRVO or INTS?

Do institutionals and insiders believe in CRVO or INTS?

Do analysts rate CRVO or INTS?

Which has more risk & volatility, CRVO or INTS?

Does the media prefer CRVO or INTS?

Is CRVO or INTS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INTS vs. The Competition

Intensity Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools